SCHEMBL11969643

SCHEMBL11969643

c1ccc(N(CCCC2CCCCN2)C2Cc3ccccc3C2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.53
HRH1 P35367 2/20 0.53
KCNH2 Q12809 2/20 0.53
HRH3 Q9Y5N1 2/20 0.53
CHRM1 P11229 1/20 0.53
DRD2 P14416 1/20 0.53
ADRA2C P18825 1/20 0.53
SLC6A2 P23975 1/20 0.53
HTR2C P28335 1/20 0.53
SLC6A4 P31645 1/20 0.53
ADRA1A P35348 1/20 0.53
OPRM1 P35372 1/20 0.53
DRD3 P35462 1/20 0.53
OPRK1 P41145 1/20 0.53
MTOR P42345 1/20 0.53
HTT P42858 1/20 0.53
SLC6A3 Q01959 1/20 0.53
GHSR Q92847 1/20 0.53
POLB P06746 1/20 0.43
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2991829 0.92 HTR2A (0.49) HTR2AHRH1KCNH2HRH3CHRM1
SCHEMBL2429656 0.92 HTR2A (0.49) HTR2AHRH1KCNH2HRH3CHRM1
SCHEMBL2426852 0.92 HTR2A (0.49) HTR2AHRH1KCNH2HRH3CHRM1
Iodide SCHEMBL29454678 0.91 HTR2A (0.48) HTR2AHRH1KCNH2HRH3CHRM1
Hydrochloric Acid SCHEMBL5968017 0.91 HTR2A (0.48) HTR2AHRH1KCNH2HRH3CHRM1
SCHEMBL11990452 0.88 GHSR (0.50) HTR2AHRH1KCNH2HRH3CHRM1
SCHEMBL20012239 0.88 GHSR (0.50) HTR2AHRH1KCNH2HRH3CHRM1
SCHEMBL13688291 0.85 HTR2A (0.42) HTR2AHRH1KCNH2HRH3CHRM1
SCHEMBL5974183 0.84 POLB (0.48) HTR2AHRH1KCNH2HRH3CHRM1
Hydrochloric Acid SCHEMBL5967902 0.83 POLB (0.47) HTR2AHRH1KCNH2HRH3CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3970723-A1 AMINOINDANE COMPOUNDS FOR USE IN TREATING UROLOGICAL PAIN Asana BioSciences, LLC (US) 2022-03-23 EP disclosed
EP-3363437-B1 AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN ENDO PHARMACEUTICALS SOLUTIONS (US) 2021-07-28 EP disclosed
CN-107540599-B Aminoindane compounds and their use to treat pain 阿萨纳生物科技有限责任公司 2021-06-04 CN disclosed
EP-3363437-A1 AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN Endo Pharmaceuticals Solutions Inc. (US) 2018-08-22 EP disclosed
EP-2675787-B1 AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN ENDO PHARMACEUTICALS INC (US) 2018-03-28 EP disclosed
US-9375423-B2 Use of aminoindane compounds in treating overactive bladder and interstitial cystitis ASANA BIOSCIENCES, LLC (US) 2016-06-28 US disclosed
US-9375423-B2 Use of aminoindane compounds in treating overactive bladder and interstitial cystitis ASANA BIOSCIENCES, LLC (US) 2016-06-28 US disclosed
US-9375423-B2 Use of aminoindane compounds in treating overactive bladder and interstitial cystitis ASANA BIOSCIENCES, LLC (US) 2016-06-28 US disclosed
US-20150290182-A1 USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS ASANA BIOSCIENCES, LLC (US) 2015-10-15 US disclosed
US-20150290182-A1 USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS ASANA BIOSCIENCES, LLC (US) 2015-10-15 US disclosed
US-20140051702-A1 Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial Cystitis ENDO PHARMACEUTICALS INC. (US) 2014-02-20 US disclosed
US-20140051702-A1 Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial Cystitis ENDO PHARMACEUTICALS INC. (US) 2014-02-20 US disclosed
US-20140051702-A1 Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial Cystitis ENDO PHARMACEUTICALS INC. (US) 2014-02-20 US disclosed
WO-2014028675-A1 USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS ENDO PHARMACEUTICALS INC. (US) 2014-02-20 WO disclosed
WO-2014028675-A1 USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS ENDO PHARMACEUTICALS INC. (US) 2014-02-20 WO disclosed
EP-2675787-A1 AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN Endo Pharmaceuticals Inc. (US) 2013-12-25 EP disclosed
WO-2012112969-A1 AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN ENDO PHARMACEUTICALS INC. (US) 2012-08-23 WO disclosed
US-20120214809-A1 Aminoindane Compounds and Use Thereof in Treating Pain Libertas Bio, Inc. 2012-08-23 US disclosed
US-20120214809-A1 Aminoindane Compounds and Use Thereof in Treating Pain Libertas Bio, Inc. 2012-08-23 US disclosed
US-20120214809-A1 Aminoindane Compounds and Use Thereof in Treating Pain Libertas Bio, Inc. 2012-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214809-A1 Aminoindane Compounds and Use Thereof in Treating Pain TRPA1, TRPV1, TRPV2 HTR2A 84/4885HRH1 64/4885KCNH2 330/4885
US-20140051702-A1 Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial Cystitis IDO1, IDO2, SLC1A2 HTR2A 305/4885HRH1 310/4885KCNH2 901/4885
US-20150290182-A1 USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS IDO1, IDO2, SLC1A2 HTR2A 305/4885HRH1 310/4885KCNH2 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.